Piramal Pharma Joins Forces with IntoCell for ADC Development

Piramal Pharma Solutions, a global contract development and manufacturing organization (CDMO) under Piramal Pharma Ltd., has signed a Memorandum of Understanding (MOU) with Korean biotech company IntoCell Inc.

The partnership focuses on collaboration in antibody-drug conjugate (ADC) development. Under this non-exclusive, non-binding agreement, IntoCell will explore licensing its drug-linker technologies with Piramal’s clients.

In return, Piramal will provide research, development, and manufacturing services for bioconjugates, including ADCs, to IntoCell and its clients.

Also Read: New Dynamics of Drug Distribution, Free Medicine Schemes in India

The partnership also strengthens Piramal’s ADCelerate platform, a rapid, integrated approach for bioconjugate development and manufacturing, by using IntoCell’s resources to streamline the path from concept to clinic.

Tae Kyo Park, CEO of IntoCell Inc., stated, "We are pleased to collaborate with Piramal Pharma Solutions, a leading CDMO. We will do our utmost to ensure the mutual success of both companies by combining our respective areas of expertise."

"By combining IntoCell's groundbreaking drug-linker technologies with our extensive expertise in bioconjugates, we position ourselves as the ideal partner for clients innovating in this critical segment," said Peter DeYoung, CEO, Piramal Global Pharma. "This collaboration significantly enhances our capabilities, empowering us to redefine the future of ADCs and drive better outcomes for patients worldwide."

The collaboration expands Piramal’s capabilities in payload-linker and bioconjugation technology. It allows the company to offer a wider range of payload-linkers and faster bioconjugate development, improving service options and competitiveness.

The licensing agreement covers IntoCell’s drug-linker technologies, including the OHPAS linker, Duocarmycin-based OHPAS payload, Nexatecan-based OHPAS payload, and iso-Nexatecan-based GGFG payload.